Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | CASP4 | P49662 | 1/20 | 0.43 |
| ▸ | CASP5 | P51878 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10058377 | 0.82 | BCL2 (0.51) | ALDH1A1MAPTKDM4EVCAM1 | |
| SCHEMBL4301297 | 0.76 | MAPT (0.59) | KMT2AALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL12733342 | 0.75 | MAPT (0.61) | KMT2AALDH1A1LMNAMAPTMAPK1 | |
| SCHEMBL1114104 | 0.74 | BCL2 (0.49) | — | |
| SCHEMBL1677443 | 0.74 | BCL2 (0.49) | — | |
| SCHEMBL82777 | 0.73 | MAPT (0.60) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL1114152 | 0.73 | MAPT (0.60) | POLBALDH1A1MAPTMAPK1HTT | |
| SCHEMBL16318379 | 0.72 | VCAM1 (0.50) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL16318378 | 0.72 | VCAM1 (0.50) | MEN1KMT2AALDH1A1LMNAMAPT | |
| SCHEMBL10058378 | 0.71 | LMNA (0.46) | MEN1KMT2AALDH1A1LMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2094672-B1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH INC (US) | 2013-05-29 | — | — | EP | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-8168645-B2 | Arylsulfonamide compounds | GENENTECH, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| CN-102105449-A | Arylsulfonamide compounds, compositions and methods of use | GENENTECH INC | 2011-06-22 | — | — | CN | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAELL JONATHAN BAYLDON | 2011-04-28 | — | — | US | disclosed |
| EP-2279174-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Genentech, Inc. (US) | 2011-02-02 | — | — | EP | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | GENENTECH, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009143246-A2 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056517-A1 | ARYLSULFONAMIDE COMPOUNDS | BCL2A1, BCL2, BAX | MEN1 1939/4885KMT2A 2054/4885POLB 2759/4885 |
| US-20110098305-A1 | ARYLSULFONAMIDE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | BAX, API5, BCL2 | MEN1 4598/4885KMT2A 4447/4885POLB 2107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.